Intervention

PT-112

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions3

Lead sponsors shown2

Clinical trials

2 shown

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With AvelumabNCT03409458 · 2018-04-24

An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation StudyNCT02884479 · 2016-08-01

Common conditions

Advanced Solid Tumor1 Non-Small Cell Lung Cancer1 Non-Small Cell Lung Cancer (NSCLC)1

Leading sponsors

Promontory Therapeutics Inc.1 SciClone Pharmaceuticals International (Cayman) Development Limited1

Trial status mix

COMPLETED1

UNKNOWN1

Phase mix

PHASE12

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.